[Chronic lymphoid leukemia and intravenous immunoglobulins].
Feugier
P
P
Service d'hématologie adulte, CHU Brabois, allée du Morvan, 54511 Vandoeuvre, France. p.feugier@chu-nancy.fr
Tomowiak
C
C
Daguindau
N
N
Perrot
A
A
D000361:Agammaglobulinemia / Q000150:complications; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007239:Infections / Q000150:complications; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D008297:Male; D015337:Multicenter Studies as Topic; D011379:Prognosis; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine